Pyridine based dual binding site aromatase (CYP19A1) inhibitors

Aromatase (CYP19A1) inhibitors are the mainstay therapeutics for the treatment of hormone dependant breast cancer, which accounts for approximately 70% of all breast cancer cases. However, increased resistance to the clinically used aromatase inhibitors, including letrozole and anastrazole, and off...

Descripción completa

Detalles Bibliográficos
Autores principales: Eissa, Ahmed G., Powell, Lauren E., Gee, Julia, Foster, Paul A., Simons, Claire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: RSC 2023
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945863/
https://www.ncbi.nlm.nih.gov/pubmed/36846364
http://dx.doi.org/10.1039/d2md00352j

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945863/
https://www.ncbi.nlm.nih.gov/pubmed/36846364
http://dx.doi.org/10.1039/d2md00352j

Ejemplares similares